AstraZeneca Highlights Continued Progress of Oncology Pipeline at ASCO 2016 Leadership in DNA Damage Response Therapies

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive investigational oncology pipeline at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2016. Highlights will include new data demonstrating the strength and versatility of AstraZeneca‚Äôs industry-leading line of DNA damage response (DDR) medicines in multiple types of cancer. New data will highlight t
Source: BusinessWire-Primary

AstraZeneca Highlights Continued Progress of Oncology Pipeline at ASCO 2016 Leadership in DNA Damage Response Therapies